Intrahepatic Cholangiocarcinoma
Conditions
Interventions
Hepatic Arterial Infusion Chemotherapy (HAIC):None
Sponsors
The second affiliated hospital of nanchang university
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Histologically or cytologically confirmed intrahepatic cholangiocarcinoma (ICC); 2.Age >= 18 years; 3.Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 4. Documented failure of first-line standard systemic chemotherapy, followed by second-line treatment with HAIC combined with systemic therapy (chemotherapy, targeted therapy, and/or immunotherapy). First-line standard chemotherapy was defined as a gemcitabine plus platinum-based doublet regimen. *Failure of first-line therapy was defined as: disease progression during treatment or within 6 months after the last dose or discontinuation due to intolerable toxicity; 5. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Exclusion criteria
Exclusion criteria: 1.Patients with a history of histologically or cytologically confirmed components of fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or cholangiocarcinoma (other than the specified intrahepatic cholangiocarcinoma under study); 2.Patients with missing baseline data or unavailable survival status; 3.Women who are pregnant or lactating; 4.Patients with significant arteriovenous shunting; 5.Contraindications to interventional therapy, such as:Severe hepatic cirrhosis/Moderate to large amounts of ascites/Child-Pugh class C liver function 6.Severe dysfunction of vital organs (e.g., heart, brain, lungs); 7.Uncontrolled conditions including hypertension, gastrointestinal bleeding, or coagulation disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Treatment-related adverse events;Changes in tumor markers; | — |
Countries
China
Contacts
Public ContactYe Mao
The second affiliated hospital of nanchang university
Outcome results
None listed